Key result
Rivaroxaban does not trigger in vitro platelet activation with HIT antibodies unlike UFH and enoxaparin.
Why the study?
Does rivaroxaban avoid platelet activation and PF4 interaction in the presence of HIT antibodies compared to heparins in vitro?
Does rivaroxaban avoid platelet activation and PF4 interaction in the presence of HIT antibodies compared to heparins in vitro?
In vitro evidence demonstrates that rivaroxaban does not cross-react with HIT antibodies or interact with PF4, suggesting it may be a suitable anticoagulant for patients with HIT.
Answers are grounded in this paper and cite their sources.
Should not alter HIT management; hypothesis-generating in vitro data require clinical validation.
Rivaroxaban is an oral, direct activated Factor Xa (FXa) inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders. Currently available anticoagulants include unfractionated heparin (UFH) and low molecular weight heparins (LMWHs); however, their use can be restricted by heparin-induced thrombocytopenia (HIT). HIT is usually caused by the production of antibodies to a complex of heparin and platelet factor-4 (PF4). This study was performed to evaluate, in vitro, the potential of rivaroxaban as an anticoagulant for the management of patients with HIT. UFH, the LMWH enoxaparin, fondaparinux and the direct thrombin inhibitor argatroban were tested to enable comparative analyses. Rivaroxaban did not cause platelet activation or aggregation in the presence of HIT antibodies, unlike UFH and enoxaparin, suggesting that rivaroxaban does not cross-react with HIT antibodies. Furthermore, rivaroxaban did not cause the release of PF4 from platelets and did not interact with PF4, unlike UFH and enoxaparin. These findings suggest that rivaroxaban may be a suitable anticoagulant for the management of patients with HIT.
No takes yet. Share an insight, caveat, or question.
Walenga et al. (2008) studied Heparin-induced thrombocytopenia (HIT). Rivaroxaban vs. Unfractionated heparin (UFH), enoxaparin, fondaparinux, argatroban was evaluated on Platelet activation or aggregation in the presence of HIT antibodies and release of PF4. In vitro, rivaroxaban did not cause platelet activation, aggregation, or PF4 release in the presence of HIT antibodies, unlike UFH and enoxaparin.
Synapse has enriched 10 related papers. Consider them for comparative context: